Track topics on Twitter Track topics that are important to you
Phoenix, United States; 9 November; and Melbourne, Australia; 10 November 2011: Regenerative medicine company, Mesoblast Limited (ASX: MSB), today announced that a single intravenous injection of its proprietary adult stem cells resulted in significant lowering of blood sugar levels for up to eight weeks in a controlled, randomized preclinical trial in non-human primates with Type 2 diabetes. This was accompanied by significant reductions in circulating inflammatory markers to levels associated with protection against heart attacks and death in patients with Type 2 diabetes. Results of the study were presented at the Credit Suisse Healthcare conference in Phoenix, Arizona.
A randomized, placebo-controlled study was performed in 17 non-human primates with dietary-induced Type 2 diabetes to evaluate the effects of a single intravenous injection of Mesoblast's proprietary allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) on blood glucose levels over an eight week period. Controls (n=3) received a single saline injection, while four groups of treated subjects (3-4 per group) received one of 4 escalating doses of MPCs (0.1, 0.3, 1 and 2 million MPCs/kg).
At baseline, the high mean fasting blood glucose levels were not significantly different between any of the Type 2 diabetic groups. Over the eight week period of the study, the control group showed no significant changes in the high levels of fasting blood glucose. In contrast, a single injection of MPCs at every dose tested significantly reduced fasting blood glucose levels as early as two weeks (p<0.001 for each dose), with a clinically meaningful reduction in fasting blood sugar levels of up to 80 mg/dl by four weeks. There was a dose-dependent effect, with the highest three MPC doses maintaining sustained reductions in fasting blood glucose over the entire eight week study period, and the lowest MPC dose being least effective. Over the eight weeks, the groups receiving 1 and 2 million MPC/kg maintained significantly lower mean fasting blood glucose levels compared with the control group (respectively, 119 mg/dl and 110 mg/dl vs 154 mg/dl, both p<0.05). The mean fasting blood glucose level in the group which received 0.3 million MPC/kg (130 mg/dl) was moderately lower than the controls (154 mg/dl), while the lowest dose at 0.1 million MPC/kg was without effect (160 mg/dl vs 154 mg/dl).
In MPC treated subjects, there was a direct correlation between reductions in fasting blood glucose levels over time and reductions in circulating C-reactive protein (CRP). CRP is a major inflammatory marker which is highly predictive of risk for heart attack and cardiac death when present at levels >3 mg/L in people with Type 2 diabetes. At eight weeks, mean CRP levels were 1.3 mg/L, 1.1 mg/L and 1.6 mg/L in the groups who received 0.3, 1 and 2 million MPC/kg, compared with 3.9 mg/L and 4.9 mg/L in the groups who received saline and 0.1 million MPC/kg, respectively (p<0.05 for the pooled highest three doses vs pooled controls and lowest dose).
These results in non-human primates build on an earlier study which showed that a single dose of human MPCs injected into mice with diabetes resulted in a significant increase in blood insulin levels and sustained reduction in blood glucose levels for the entire three-week period of follow-up. This was due to restoration in the damaged pancreas of the balance between insulin-producing beta cells, which reduce blood glucose, and glucagon-producing alpha cells, which increase blood glucose.
Mesoblast Chief Executive, Professor Silviu Itescu, said that the results obtained to date indicate that a single intravenous injection of Mesoblast’s MPCs may have a sustained benefit on blood glucose control, reduce inflammation, and improve lipid profile in patients with Type 2 diabetes.
"Mesoblast’s cells have the potential to establish a new medical paradigm for the treatment of Type 2 diabetes which is safe and simultaneously targets multiple factors responsible for the disease and its complications.
"Intravenous injection of our MPCs may not only improve blood glucose control, it may concomitantly reduce the significant risk of heart attacks and death that occurs in patients with Type 2 diabetes," Professor Itescu added.
Mesoblast has an upcoming scheduled meeting with the United States Food and Drug Administration (FDA) to discuss its Phase 2 clinical program in patients with Type 2 diabetes. The company expects to commence a randomized, placebo-controlled Phase 2 trial in the first quarter of 2012.
Type 2 diabetes accounts for 90-95 per cent of the 230 million diabetics in the western world, with its prevalence increasing at an alarming rate. In the United States alone, there were 27 million established cases of Type 2 diabetes in adults aged over 20 in 2010. With a growth rate of 2.6% per year, this number is expected to increase to more than 35 million in 2020.
Mesoblast Limited (ASX:MSB) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com
For further information, please contact:
T: + 61 (0) 3 9639 6036
For media enquiries in Europe, please contact:
Melanie Toyne Sewell/Daniel Gooch/Gemma Howe
College Hill Life Sciences
T: +44 (0)20 7866 7860
Investment snapshot Issued shares 280m
Current share price A$8.23
Cash available (approx) A$256m
Market capitalization A$2,300m
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...